# Giuseppe Viale

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/giuseppe-viale/

## Facts

| Field | Value |
| --- | --- |
| Citations | 112,610 |
| Field | Breast Cancer Treatment Studies |
| h-index | 157 |
| i10-index | 681 |
| Last Known Institution | European School of Oncology |
| OpenAlex ID | https://openalex.org/A5088697304 |
| ORCID iD | https://orcid.org/0000-0003-1882-7068 |
| Works | 1,266 |

## Researcher papers

Showing 12 of 21.

- [Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013](https://scholariq.org/papers/personalizing-the-treatment-of-women-with-early-breast-cancer-highlights-of-the/)
- [The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014](https://scholariq.org/papers/the-evaluation-of-tumor-infiltrating-lymphocytes-tils-in-breast-cancer/)
- [70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer](https://scholariq.org/papers/70-gene-signature-as-an-aid-to-treatment-decisions-in-early-stage-breast-cancer/)
- [Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer](https://scholariq.org/papers/adjuvant-olaparib-for-patients-with-i-brca1-i-or-i-brca2-i-mutated-breast-cancer/)
- [Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update](https://scholariq.org/papers/estrogen-and-progesterone-receptor-testing-in-breast-cancer-asco-cap-guideline/)
- [De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017](https://scholariq.org/papers/de-escalating-and-escalating-treatments-for-early-stage-breast-cancer-the-st/)
- [Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials](https://scholariq.org/papers/long-term-outcomes-for-neoadjuvant-versus-adjuvant-chemotherapy-in-early-breast/)
- [Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis](https://scholariq.org/papers/cancer-immunotherapy-efficacy-and-patients-sex-a-systematic-review-and-meta/)
- [Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors](https://scholariq.org/papers/assessing-tumor-infiltrating-lymphocytes-in-solid-tumors-a-practical-review-for/)
- [Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research](https://scholariq.org/papers/assessing-tumor-infiltrating-lymphocytes-in-solid-tumors-a-practical-review-for-2/)
- [A gut-vascular barrier controls the systemic dissemination of bacteria](https://scholariq.org/papers/a-gut-vascular-barrier-controls-the-systemic-dissemination-of-bacteria/)
- [Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial](https://scholariq.org/papers/pembrolizumab-plus-trastuzumab-in-trastuzumab-resistant-advanced-her2-positive/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Breast Lesions and Carcinomas](https://scholariq.org/topics/breast-lesions-and-carcinomas/)
- [Estrogen and related hormone effects](https://scholariq.org/topics/estrogen-and-related-hormone-effects/)

## Researcher university

- [European School of Oncology](https://scholariq.org/institutions/european-school-of-oncology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.